Physician profile
Wade E Lenz
NPI 1255383469
$1,671.69
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $739 · 2022: $393 · 2023: $410 · 2024: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.52 | 2021-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $201.90 | 2022-2024 | Shingrix, Arexvy, Boostrix |
| Abbvie INC. | $150.80 | 2021-2024 | |
| Abbott Laboratories | $105.31 | 2022-2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $88.64 | 2022-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $82.18 | 2021-2024 | |
| Lilly USA, LLC | $78.80 | 2021-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $64.22 | 2021-2022 | |
| Pfizer INC. | $61.48 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.79 | 2021 | |
| Esperion Therapeutics, INC. | $37.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.57 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $32.99 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $26.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.11 | 2021 | |
| Eisai INC. | $24.46 | 2021 | |
| Mylan Specialty L.P. | $22.84 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.18 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $16.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Lenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.